October 23, 2016 | PR Web —
North America’s fastest growing healthcare machine learning company, HealthNextGen, has teamed with Europe’s largest University Hospital, Charité – Universitätsmedizin Berlin to predict the risk of hospitalization arising due to Myasthenia gravis.
North America’s fastest growing healthcare machine learning company, HealthNextGen, has teamed with Europe’s largest University Hospital, Charité – Universitätsmedizin Berlin. Charité has selected HealthNextGen’s flagship platform, [email protected] to predict the risk of hospitalization arising due to Myasthenia gravis. The platform will also help doctors predict patient response to treatment.
Charité’s Integrated Myasthenia Center at the NeuroCure Clinical Research Center is currently working with HealthNextGen, a clinical artificial intelligence start-up to predict Myasthenic crisis and response to therapy for their patients as well as provide objective clinical decision support for their treatment plans. [email protected] will also allow Charité researchers to potentially identify biomarkers impacting patient outcomes. The new platform will allow doctors the capability of early intervention and an alternate treatment plan.
Dr. Philipp Mergenthaler, MD, Principal Investigator for Charité – Universitätsmedizin Berlin and fellow of the Charité – Berlin Institute of Health Clinical Scientist Program said, “Our collaboration with HNG will open the way for targeted immunosuppressive treatment for our patients and personalized medicine in Myasthenia gravis.“
“We couldn’t have had a better partner for this project than Charité,” said Santosh Hariharan, Chief Technical Officer, HealthNextGen. “We are now in a unique position to apply HealthNextGen’s leading deep machine learning and analytic capabilities to truly make a difference in the lives of Myasthenia gravis patients. “This is also a great opportunity for us to drive care quality, reduce costs, and improve patient outcomes for this rare disease.”
In addition, the platform will allow neurologists to proactively predict patient response to drug treatments and manage quality outcomes, cost, and utilization. It will also help establish boundaries for personalized medicine within the scope of the disease.
Dr. Andreas Meisel, MD, Professor of Neurology and Head of the Integrated Myasthenia Center said: “Using machine learning to predict response to therapy may change the way we treat Myasthenia gravis and possibly other rare diseases.”
This will in-turn help Charité improve patient outcomes; efficiently use health system resources while at the same time driving improvements in the quality of care.
“This is a significant milestone for HealthNextGen,” said Hubert Zajicek, CEO of Health Wildcatters. “They are part of our current accelerator class and we are thrilled they are partnering with one of the most prestigious hospitals in Europe to offer a solution that can transform the future of caring for patients with Myasthenia gravis and other diseases.”
About Charité – Universitätsmedizin Berlin
With a total of 3,001 beds, Charité – Universitätsmedizin Berlin is one of the largest university hospitals in Europe. Charité spans 4 campuses and comprises approximately 100 Departments and Institutes. In 2015, Charité treated more than 142,000 outpatient and more than 663,000 inpatient cases. With approximately 16,900 staff employed across the Charité group of companies, Charité is one of the largest employers in Berlin. In 2015, the Charité university hospital recorded a turnover of more than €1.6 billion. The areas of research, teaching, and health care delivery are intricately linked, resulting in a working relationship that is characterized by interdisciplinary cooperation. In 2015, Charité was able to secure more than €149 million in third-party funding, as well as approximately €202 million in state funding for research and teaching. With approximately 7,000 future physicians and dentists currently enrolled in degree courses, Charité is one of the largest medical faculties in Germany. http://www.charite.de/
HealthNextGen is a Clinical Artificial Intelligence start-up that develops software designed to predict hospitalization events, recommend personalize prescriptions, predict disease complications and financial loss for providers, with a mission is to provide personalized healthcare to improve patient outcomes and reduce costs. The company offers a suite of solutions that combine clinical intelligence, medical sensor devices data along with machine learning solution to protect provider revenues, improve clinical efficacy and early intervention to improve patient outcomes. To learn more about HealthNextGen’s solutions, please visit http://www.healthnextgen.com
This content appears as it was originally published on PR Web.0